ArticleClinical, cosmetic and investigational dermatology2026
Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urticarial vasculitis (UV) is a clinicopathologic entity characterized by urticarial lesions disclosing histopatho logically leukocytoclastic vasculitis, mainly of postcapillary venules. A 61-year-old woman with a four-month history of widespread, pruritic urticarial lesions was diagnosed with urticarial vasculitis. The patient received a subcutaneous injection of Omalizumab (300 mg) every 28 days, combined with oral Cyclosporine (3 mg/kg/day). Significant clinical improvement was noted within five days post-treatment. This case highlights the difficulties in treating refractory urticarial vasculitis while demonstrating the successful use of Omalizumab plus Cyclosporine, providing a viable treatment option for similar patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.